Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metagenome analysis for immunotherapy-treated patients with NSCLC

ABSTRACT: Metagenome analysis

PROVIDER: PRJEB69295 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gut resistome of NSCLC patients treated with immunotherapy.

Project description: Not available

| S-EPMC11335565 | biostudies-literature

Soil metagenome from avocado orchards in Channybearup, Western Australia in 2024

Project description:Metagenome data from soil samples were collected at 0 to 10cm deep from 2 avocado orchards in Channybearup, Western Australia, in 2024. Amplicon sequence variant (ASV) tables were constructed based on the DADA2 pipeline with default parameters.

2025-06-15 | GSE298403 | GEO

TMB in NSCLC patients treated with combination immunotherapy

Project description:Tumor mutation burden estimated with whole exome sequencing of 43 NSCLC patient tumors treated with anti-PD-1 + anti-CTLA-4

2018-02-15 | PRJEB24995 | EVA

Circulating proteins detected by SWATH-MS in metastatic NSCLC patients treated with immunotherapy.

Project description:Immunotherapy has improved survival rates in NSCLC patients, but identifying those who will respond to treatment remains a challenge. We performed a differential proteomic quantitative analysis based on SWATH–MS technology to analyse the proteome in blood samples collected from patients with advanced NSCLC prior to the start therapy and during the therapy

2025-02-18 | PXD042091 | Pride

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy.

Project description: Not available

| S-EPMC10042886 | biostudies-literature

Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy.

Project description: Not available

| S-EPMC8303258 | biostudies-literature

Immunotherapy in previously treated non-small cell lung cancer (NSCLC).

Project description: Not available

| S-EPMC5861264 | biostudies-literature

Fruit and vegetable supplemented-diet ameliorates dextran sodium sulfate (DSS) -induced colitis by modulating host transcriptome and gut metagenome response

Project description:Dietary intake of fruits and vegetables (FV) has been inversely associated with lower risk of ulcerative colitis. A pig model was used to evaluate the impact of feeding FV on the host response to dextran sulfate sodium (DSS)-induced colitis. Methods: Six-week-old pigs were fed a grower diet alone or supplemented with lyophilized FV equivalent to the half (half-FV) or full (full-FV) daily levels recommended for humans by the Dietary Guidelines for Americans (DGA). Pigs were fed a 1) grower diet alone (negative control), 2) grower diet and orally treated with 4% DSS for 10 days to induce colitis (positive control), 3) half-FV diet treated with 4% DSS or 4) full-FV diet treated with 4% DSS. Pigs were monitored for the development of clinical signs of colitis. Proximal colon (PC) contents and mucosa (PCM) were collected for gut metagenome, tissue transcriptome and histopathological analysis. Results: Pigs fed the full-FV diet did not exhibit diarrhea, showed less fecal occult blood (FOB), PCM crypt hyperplasia but with no differential expressed genes (DEG) or changes in PC microbiome diversity (p < 0.05). Pigs within the half-FV group exhibited increased group FOB and DEG associated with tissue remodeling, crypt and goblet cell hyperplasia in the PCM and no changes in PC microbiome diversity and two pigs exhibiting diarrhea (p < 0.05). Pigs within the DSS positive control group exhibited a reduced DEG involved with intestinal immune response and PC microbiome diversity with altered metagenome, increased group PCM erosion and FOB with persistent diarrhea in one pig (p < 0.05) Conclusions: Overall, our results showed that pigs fed a three-week full-FV supplemented diet, were resistant to DSS-induced colitis with a differential dose-dependent protective effect on host intestinal tissue and gut metagenome when exposed to an inflammatory challenge.

2026-04-01 | GSE317287 | GEO

Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.

Project description: Not available

| S-EPMC9400786 | biostudies-literature

Immunotherapy in NSCLC Patients with Brain Metastases.

Project description: Not available

| S-EPMC9267075 | biostudies-literature